Abiraterone with or without Food? A Retrospective pilot study On Determining the effect of abiraterone Intake with food on Toxicity and life-Expectancy in mCRPC patients

Abstract

Methods. In this retrospective observational cohort-study, patients were divided in a fasted-group and fed-group. Progression free survival and overall survival were compared between the two groups, using Kaplan-Meier analysis with log-rank test. Toxicity was measured as incidence of side-effects. Results. 26 patients were included in the fed-group and 72 patients were included in the fasted-group. The fed-group had a median progression free survival of 315 days (IQR 154-436 days), the fasted-group had a median progression free survival of 230 days (IQR 140-431 days). Patients who were diagnosed with gleason score 8 and had received prior docetaxel treatment had a median progression free survival of 315 days (IQR 210-723 days) in the fed-group and 155 days (IQR 82-288 days)in the fasted group. Median overall survival was not reached for the fed-group. Toxicity risk was similar in both groups. Interpretation. Concomitant intake of AA with food does not lead to prolonged survival. However, patients who were diagnosed with gleason score 8 or higher and had prior chemotherapy saw a modest, non-significant, improvement in progression free survival. These results demonstrate that it is feasible to investigate the food effect in specific patient populations in a larger randomized prospective study, and is therefore recommended.